186430-23-9

Upstream product

• 10517-21-2 5-chloro-1H-Indole-2-carboxylic acid 
• 5382-17-2 piperidin-4-ol hydrochloride 
• 41153-30-4 Boc-Phe(p-F) 
• 186431-68-5 [(S)-1-(4-Fluoro-benzyl)-2-(4-hydroxy-piperidin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Use of glycogen phosphorylase inhibitors

The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

Tetrazole compounds as thyroid receptor ligands

The present invention relates to tetrazole compounds of Formula I, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, and pharmaceutically acceptable salts of the prodrugs. The invention also relates to compositions comprising the tetrazole compounds and to methods of treating obesity, diabetes, atherosclerosis, hypertension, coronary heart disease, hypercholesterolemia, hyperlipidemia, thyroid disease, thyroid cancer, hypothyroidism, depression, glaucoma, cardiac arrhythmias, congestive heart failure, and osteoporosis using the tetrazole compounds.

Use of glycogen phosphorylase inhibitors to inhibit tumor growth

This invention relates to the use of glycogen phosphorylase inhibitors of Formula I or Formula IA: 1as defined herein, and their pharmaceutically acceptable salts and prodrugs thereof, to inhibit abnormal cell growth in mammals, including humans. The invention also relates to pharmaceutical compositions containing glycogen phosphorylase inhibitors alone or in combination with other glycogen phosphorylase inhibitors or other inhibitors of abnormal cell growth, and to methods of treating cancer, hyperproliferative disorders, or abnormal cell growth in a mammal by administering to a mammal in need thereof the compounds and compositions of the invention.

Processes and intermediates for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid

The present invention provides novel processes for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid. Also provided are novel intermediates used in those processes. Further, the 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid prepared by the novel processes can be further reacted to yield known indole 2-carboxamides and derivatives thereof possessing glycogen phosphorylase inhibitory activity, which are useful in the treatment of mammals, especially human beings, having glycogen phosphorylase dependent diseases or conditions.

Use of glycogen phosphorylase inhibitors to inhibit tumor growth

This invention relates to the use of glycogen phosphorylase inhibitors of Formula I or Formula IA: as defined herein, and their pharmaceutically acceptable salts and prodrugs thereof, to inhibit abnormal cell growth in mammals, including humans. The invention also relates to pharmaceutical compositions containing glycogen phosphorylase inhibitors alone or in combination with other glycogen phosphorylase inhibitors or other inhibitors of abnormal cell growth, and to methods of treating cancer, hyperproliferative disorders, or abnormal cell growth in a mammal by administering to a mammal in need thereof the compounds and compositions of the invention.

Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides

Processes and intermediates for preparing compounds of Formula (I).

Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors

The present invention provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having or at risk of having diabetic cardiomyopathy a therapeutically effective amount of a glycogen phosphorylase inhibitor. The

Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection

A pharmaceutical composition containing a glycogen phosphorylase inhibitor of Formula I or IA as defined herein is administered to a mammal to treat infection.

Pharmaceutical compositions of glycogen phosphorylase inhibitors

Pharmaceutical compositions comprise a glycogen phosphorylase inhibitor and at least one concentration-enhancing polymer. The composition may be a simple physical mixture of glycogen phosphorylase inhibitor and concentration-enhancing polymer or a dispersion of glycogen phosphorylase inhibitor and polymer.

Use of heteroaryl substituted N-(Indole-2-Carbonyl-) amides for the manufacture of a medicament for the treatment of infection

Glycogen phosphorylase inhibitors, including those of Formula I or IA as defined herein, can be used to treat infection in a mammal.